Diagnósticos da América (DASA3) Q3 2024 earnings summary

Executive summary

• Achieved operational efficiency and productivity gains, with international recognition for hospital excellence and sustainability, and best NPS ratings of the year.

• Strategic focus on margin optimization, operational excellence, and divestment of non-core assets, including the sale of Dasa Empresas for R$255 million.

• Net loss narrowed to R$87 million in 3Q24, a 52% improvement over 3Q23, mainly due to EBITDA growth.

• Ongoing restructuring, process revisions, and organizational changes to align with core business and optimize G&A.

• Progress on joint venture with Amil for hospital and oncology assets, creating a major hospital network.

Financial highlights

• Gross revenue reached R$4.3 billion in 3Q24, up 6% year-over-year; net revenue was R$4.0 billion, up 5% year-over-year.

• EBITDA grew 14% year-over-year to R$751 million, with margin up 1.4 p.p. to 18.9%.

• Adjusted expenses reduced by 12% year-over-year, reflecting operational efficiency.

• Investments totaled R$137 million in 3Q24, a 19% reduction year-over-year, with focus on high-return projects.

• Cash and equivalents at R$2.8 billion, covering 1.4x–1.5x debts maturing by end-2025.

Outlook and guidance

• Continued focus on core businesses (hospitals, oncology, diagnostics), with non-core asset divestitures and international exit ongoing.

• Optimism for further G&A optimization, margin improvement, and deleveraging in the coming year.

• Investment budget for 2024 set at R$565 million, a 22% reduction from 2023.

• Focus on high-return expansion projects, asset maintenance, and technology services.